Detalhe da pesquisa
1.
Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial.
Brain Behav Immun
; 115: 191-200, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37848096
2.
A stepped wedge cluster randomised trial of a cognitive remediation intervention in alcohol and other drug (AOD) residential treatment services.
BMC Psychiatry
; 19(1): 70, 2019 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30760250
3.
Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder.
J Neuroinflammation
; 14(1): 188, 2017 Sep 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-28923068
4.
The Impact of Childhood Adversity on Cognitive Development in Schizophrenia.
Schizophr Bull
; 46(1): 140-153, 2020 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31050754
5.
Cognitive outcomes of pediatric stroke.
Child Neuropsychol
; 24(3): 287-303, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27960625
6.
C-Reactive Protein: Higher During Acute Psychotic Episodes and Related to Cortical Thickness in Schizophrenia and Healthy Controls.
Front Immunol
; 9: 2230, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30364161
7.
Cognitive Subtypes of Schizophrenia Characterized by Differential Brain Volumetric Reductions and Cognitive Decline.
JAMA Psychiatry
; 73(12): 1251-1259, 2016 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27829096
8.
The impact of premorbid and current intellect in schizophrenia: cognitive, symptom, and functional outcomes.
NPJ Schizophr
; 1: 15043, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-27336046